Overview
Veronica Mariotti practices practicing medicine in Pisa, Italy.
Her clinical expertise encompasses Chronic Myelogenous Leukemia (CML) and Antisocial Personality Disorder.
She is actively involved in clinical research, co-authoring 17 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Veronica Mariotti
Is Veronica Mariotti a top-rated expert for Chronic Myelogenous Leukemia (CML)?
MediFind is an objective health platform that identifies experts based on real-world data. Veronica Mariotti is classified as an Experienced expert for Chronic Myelogenous Leukemia (CML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Veronica Mariotti participate in research or clinical trials?
Yes. Veronica Mariotti has published 17 articles and abstracts on conditions like Chronic Myelogenous Leukemia (CML). You can view a list of Veronica Mariotti's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Antisocial Personality DisorderMs. Mariotti isExperienced. Learn about Antisocial Personality Disorder.
- Chronic Myelogenous Leukemia (CML)Ms. Mariotti isExperienced. Learn about Chronic Myelogenous Leukemia (CML).